Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator
    Liu, Shi-Ying
    Cao, Wen-Feng
    Wu, Ling-Feng
    Xiang, Zheng-Bing
    Liu, Shi-Min
    Liu, Hai-Yan
    Pan, Yang
    Nie, Feng
    Wu, Xiao-Mu
    Xie, Xu-Fang
    MEDICINE, 2018, 97 (49)
  • [42] Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
    Chenna, Vijay
    Kaul, Subhash
    Tandra, Swetha
    Yareeda, Sireesha
    Mathukumalli, Neeharika
    Kohat, Abhijeet Kumar
    Kandadai, Rukmini Mridula
    Turaga, Suryaprabha
    Sheik, Jabeen Afshan
    Meena, A. K.
    Borgohain, Rupam
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2018, 21 (03) : 214 - 219
  • [43] Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator
    Bo-Lin Ho
    Chien-Fu Chen
    Ruey-Tay Lin
    Ching-Kuan Liu
    A-Ching Chao
    Neurological Sciences, 2016, 37 : 1799 - 1805
  • [44] Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment
    Vandelli, Laura
    Marietta, Marco
    Trenti, Tommaso
    Varani, Manuela
    Bigliardi, Guido
    Rosafio, Francesca
    Dell'Acqua, Maria Luisa
    Picchetto, Livio
    Nichelli, Paolo
    Zini, Andrea
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (02): : 219 - 222
  • [45] Current Status and Future of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
    Sakaida, Hiroshi
    Taki, Waro
    NEUROLOGICAL SURGERY, 2009, 37 (11): : 1067 - 1083
  • [46] The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke
    Buijs, Julie E.
    Uyttenboogaart, Maarten
    Brouns, Raf
    de Keyser, Jacques
    Kamphuisen, Pieter Willem
    Luijckx, Gert-Jan
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (02) : 312 - 316
  • [47] Low-Dose Versus Standard-Dose Tissue Plasminogen Activator for Intravenous Thrombolysis in Asian Acute Ischemic Stroke Patients
    Ng, Kay W. P.
    Sharma, Vijay K.
    STROKE, 2010, 41 (08) : E545 - E546
  • [48] Intravenous Recombinant Tissue-Type Plasminogen Activator: Influence on Outcome in Anterior Circulation Ischemic Stroke Treated by Mechanical Thrombectomy
    Ferrigno, Marc
    Bricout, Nicolas
    Leys, Didier
    Estrade, Laurent
    Cordonnier, Charlotte
    Personnic, Thomas
    Kyheng, Maeva
    Henon, Hilde
    STROKE, 2018, 49 (06) : 1377 - 1385
  • [49] Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia
    Al Khathaami, Ali M.
    Al Bdah, Bayan
    Tarawneh, Maisoun
    Alskaini, Mohammed
    Alotaibi, Faris
    Alshalan, Abdulaziz
    Almuhraj, Mohammed
    Aldaham, Daham
    Alotaibi, Nasser
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2020, 29 (05)
  • [50] The Safety and Effectiveness of Low-Dose Recombinant Tissue Plasminogen Activator (0.6 mg/kg) Therapy for Elderly Acute Ischemic Stroke Patients (≥ 80 Years Old) in the Pre-endovascular Era
    Takayanagi, Shunsaku
    Ochi, Takashi
    Hanakita, Shunya
    Suzuki, Yasutaka
    Maeda, Keiichiro
    NEUROLOGIA MEDICO-CHIRURGICA, 2014, 54 (06) : 435 - 440